Points of Return
To get John Authers’ newsletter delivered directly to your inbox, sign up here. US inflation is clearly rising again. US stocks are hitting
View in browser
Bloomberg

To get John Authers’ newsletter delivered directly to your inbox, sign up here.

Today’s Points:

Jumbo Cut Would Reflect Pressure, Not Inflation

Outside food and energy, US prices are picking up again. Disinflation after the epic post-pandemic price shock is over. In other news, the latest nominee for the Federal Reserve’s board of governors is chiding his new colleagues for “tariff derangement syndrome” and the US Treasury secretary says that a jumbo cut of 50 basis points would be in order next month. And the US stock market has surged to an emphatic new record.

These things are linked, but not in the way that might first appear. The inflation numbers don’t strengthen the case for a rate cut. All else equal, they should be bad for stocks. But the intense political pressure for a rate cut has little to do with the data.

That pressure has moved the dial toward easy money. Rate cuts don’t generally happen when inflation is above target and no recession appears imminent. When they do, the stock market might well melt up. Hence Tuesday’s buying. 

Last week, the nominee Fed governor, Steven Miran, told Bloomberg there was “zero macroeconomically significant evidence of price pressures from tariffs.” If there were any effect, he said, it would be a “one-time price shift,” as happens when governments raise sales taxes, and not an enduring regime change. If the administration’s message wasn’t clear enough, Treasury’s Scott Bessent piled on to say that the Fed should consider cutting by 50 basis points next month.

It’s hard to reconcile such rhetoric with the actual numbers. This is our standard beautiful chart, dividing inflation into its four core elements:

Tariffs have their most evident effect on core goods, which are scarcely visible in the big chart. Here is the sector’s contribution to CPI in isolation:

Two points are clear. First, core goods aren’t contributing much to the overall price burden. Second, their prices usually have a tendency to go down, so even if they add only two-tenths of a percentage point to bring core CPI to 3.1%, a trend has turned. It’s not terrifying, but is concerning. Some tariffed products (like home furnishings) are already showing signs that the levies are being passed through, and others (notably new cars) aren’t:

Tiffany Wilding of Pimco offers reasons why companies are prepared to “eat” tariffs so far: Their margins are healthy, giving them space to do this; consumers are price-sensitive, so businesses selling to them will hold off on price rises as long as they can; and corporate tax cuts in the One Big Beautiful Bill Act offset the pain. Can this continue? Omair Sharif of Inflation Insights LLC warns that of 75 items within core goods, 65.3% rose in July, up from 57.3% in June and the highest in 30 months. He suggests that a wider swathe of core goods is steadily being impacted by higher tariffs. 

Services, not goods, have been leading inflation and continue to do so. Chair Jerome Powell started to look at “supercore” (core services minus shelter) as a priority, which is unfortunate as it has unambiguously turned upward, rising to 3.2% from 2.7% in April:

This might be because of concern over tariffs, a belief that the Fed will make a dovish error, or any number of things; the key is that the trend is no longer in the right direction. The same is true if we look at inflation of sticky prices, for products whose prices take a while to change and are very difficult to cut. Again, this inflation is rising again, and it never got down to the Fed’s upper bound of 3%:

The Cleveland Fed produces a median CPI, and also a trimmed mean, which excludes outliers. Both these purists’ measures of core inflation have stopped falling and started to rise, without ever getting within target range. Outside the post-pandemic spike, the median hasn’t been this high in more than three decades:

The overall numbers look good because one of the Trump 2.0 priorities, a lower oil price, is coming through in spades. Cheaper gasoline will make people much happier and brings the headline rate down to 2.7%. Exclude energy, and everything else is at 3%. It’s not at a level that would normally encourage central bankers, who generally ignore oil prices as they have no control over them, to ease rates:

The markets most closely tied to rates don’t see this inflation report as moving the needle much. A September cut is seen as a racing certainty — but that’s been the case ever since last week’s employment revision:

A rate cut is likely, and defensible, because of unemployment. This month’s huge revisions showed the labor market was much weaker than thought. But payrolls are still growing. The official unemployment rate, less susceptible to revision than the payroll figure and compiled with a different survey, rose menacingly ahead of last September’s “jumbo cut.” That seems to have halted the deterioration:

Wage inflation is falling, but not as fast as the Fed would like. These are the wage-tracker numbers produced by the Atlanta Fed from census data. Wages are rising, for both full- and part-time employees, faster than at any time in the 20 years before Covid:

Jim Bianco of Bianco Research makes the devastating point that in the last 40 years, the Fed has only once cut rates when the core was above 3% and the three-month change was greater than 0.3%. That was between October 1990 and March 1991 when there was war in the Persian Gulf and the economy slid into recession.

The Fed might now give up on its 2% target. There’s an argument for that, but the electorate seemed to feel differently last November, after the battering from inflation during Joe Biden’s presidency. As for stocks, everyone understands the potential of artificial intelligence. But the S&P 500 is trading at a record multiple of sales, so a lot is riding on keeping margins high:

Share prices shouldn’t be viewed in isolation. Lower interest rates justify higher valuations. But if we compare the S&P’s earnings yield (the inverse of the price/earnings ratio) with the 10-year Treasury yield, or its dividend yield with the three-month Treasury bill, stocks look terrible value. Those rate cuts really need to happen: 

Tariffs’ pass-through to prices to date has been weaker than many had feared. But it’s not deranged to monitor the risks, which are clear and obvious. Whether it’s deranged to pile into stocks is another matter. With a dovish error apparently in the pipeline, maybe it makes sense. 

The Magic Pill

Last Thursday, Eli Lilly & Co., maker of the blockbuster weight-loss medication Zepbound, reported earnings and revenue strongly ahead of analysts’ expectations. It topped that with a positive outlook and an upward revision to its sales guidance. There was even “better” news following an earlier announcement that data from clinical trials of its pill, orforglipron, showed that the people taking it shed as much as 27 pounds (12.2 kilograms).

Kenneth Custer, an executive vice president at the company, said there were encouraging effects on other important measures, like blood pressure, lipids, inflammatory biomarkers, and fasting glucose — the sort of things preventive health care is all about.

After all of this fantastic news, Lilly’s shares fell by 14%, the most in a quarter-century.

What was the problem? The pill seems to help lose weight as well as the injectables now on the market, but it was disappointing that its side effects were no better. Trialists recorded higher rates of nausea and vomiting than anticipated. That footnote packed a lot of punch to the company’s quest to deliver a blockbuster weight-loss pill. Rivals, led by Denmark’s Novo Nordisk A/S, couldn’t escape the blowback:

Pills are crucial to broadening the market for weight-loss medications, which is expected to grow to about $150 billion by 2032. It’s only a matter of time before the the dominance of Lilly and Nordisk is eroded by generic competition. This threat, Morningstar’s Karen Andersen argues, has fueled the race for the next blockbuster. She argues that pills have merits:

Having an oral drug is one differentiator — it could be perceived as more convenient for some patients, and might make treatment more appealing for those patients looking for a more limited level of weight loss and paying out of pocket. 

Pills are easier to distribute because they don’t require a cold chain and aren’t refrigerated. Neither do they need the elaborate “pens” that could cause shortages for the injectable versions. Eli Lilly’s pill is composed from a small molecule, making it easier to manufacture.

The market’s massive reaction to the news gives ample testament to how much Lilly’s valuation had become tied to another blockbuster breakthrough. It’s a fiercely contested and difficult race in which others like AstraZeneca Plc and Pfizer Inc. have run into setbacks of their own.

Novo Nordisk, manufacturer of Ozempic, has fared even worse. Its shares have plummeted by nearly 50% year-to-date. Europe’s most valuable company six months ago, it’s now fallen out of the top 10. The outlook was affected by preliminary results suggesting its pills don’t help weight-loss capability as much as its injectables. Its valuation has steadily declined over the past year:

While a breakthrough remains elusive, analysts covering Eli Lilly and Novo Nordisk are resolute. Daniel M. Skovronsky, Lilly’s chief scientific officer and president, said the side effects were broadly expected. They generally occur early in the treatment or when doses escalate, and then decrease over time.

Further, the chances that Medicare will cover obesity drugs are rising, as the White House is close to proposing a pilot. Bloomberg Intelligence’s Duane Wright notes that the drugs’ broad health benefits are a factor, as is a looming government price cut for semaglutide, the injectables. This could mean $35 billion in new drug spending over nine years, depending on the details:

The proposal's biggest impact could be on the Medicaid population, which has a roughly 40% obesity rate. Expanding access would address cost concerns that have slowed expansion. Thirteen state Medicaid programs cover drugs for weight loss — 11 for state employees — but continued access is in doubt. 

The program’s spending on drugs for obesity including diabetes grew at a 61% compound annual rate between 2019 and 2023. Wright believes the pilot is crucial for states facing reduced federal funding. An expansion would be a win-win, and might offer a new entry point for investors. It could be even more of a win for patients.

Richard Abbey

Survival Tips

Hamilton, the musical, has turned 10. If you haven't seen it yet, what’d you miss? There are all kinds of musings out there on its significance, and whether it hits differently now under Trump than the premiere under Obama. But if you haven’t caught up with it, you should. It’s brilliant, and I say this not just because Lin Manuel Miranda is a local hero in Washington Heights. And it still inspires meme after meme after meme after meme. Even on a phrase like “And Peggy.”

More From Bloomberg Opinion

  • Marc Champion: Putin Is About to Outplay Trump Again in Alaska
  • Hal Brands: How the US Could Lose the AI Arms Race to China
  • Thomas Black: Rare-Earth Deals Show the US Can Break China’s Grip

Want more Bloomberg Opinion? OPIN. Or you can subscribe to our daily newsletter.

Like Bloomberg's Points of Return? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters like Markets Daily or Odd Lots.

Like getting this newsletter? Subscribe to Bloomberg.com for unlimited access to trusted, data-driven journalism and subscriber-only insights.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Points of Return newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022